CVS - NYSE
CVS Health Corporation
$91.37
+0.83%CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates. Its Pharmacy Services segment offers pharmacy benefit management solutions, including plan design and administration, formulary management, retail pharmacy network management, mail order pharmacy, specialty pharmacy and infusion, clinical, and disease and medical spend management services. It serves employers, insurance companies, unions, government employee groups, health plans, prescription drug plans, Medicaid managed care plans, plans offered on public health insurance and private health insurance exchanges, other sponsors of health benefit plans, and individuals. This segment operates retail specialty pharmacy stores; and specialty mail-order, mail-order dispensing, and compounding pharmacies, as well as branches for infusion and enteral nutrition services. The company's Retail/LTC segment sells prescription and over-the-counter drugs, consumer health and beauty products, and personal care products; and provides health care services through its MinuteClinic walk-in medical clinics. This segment also distributes prescription drugs; and provides related pharmacy consulting and other ancillary services to care facilities and other care settings. As of December 31, 2021, it operated approximately 9,900 retail locations and 1,200 MinuteClinic locations, as well as online retail pharmacy websites, LTC pharmacies, and onsite pharmacies. The company was formerly known as CVS Caremark Corporation and changed its name to CVS Health Corporation in September 2014. CVS Health Corporation was founded in 1963 and is headquartered in Woonsocket, Rhode Island.
At a Glance
Live SnapshotCVS Health Corporation Profit Bridge
Profitability Analysis
Gross Margin
Thin margins leave little room for error. Cost management and pricing strategy are critical.
Operating Margin
Minimal operating profit suggests high operating costs or pricing challenges. Scalability is concerning.
Net Profit Margin
Minimal profitability after all expenses. Limited financial flexibility for reinvestment or shareholder returns.
Effective Tax Rate
Moderate tax rate typical for most corporations. Represents standard tax burden on profits.
Profitability Insight
Efficient profit conversion: Minimal margin compression from gross to net indicates lean operations and favorable tax/interest environment.
CVS Health Corporation Income Statement
CVS • NYSE
| CVS Health Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
402.1B | 372.8B | 357.8B | 322.5B | 292.1B | 268.7B | 256.8B | 194.6B | 184.8B | 177.5B | 153.3B | 139.4B | 126.8B | 123.1B | 107.1B | 95.8B | 98.2B | 87.5B | 76.3B | 43.8B | |
GROSS PROFIT | ||||||||||||||||||||
(346.7B) | (321.4B) | (303.3B) | (268B) | (240B) | (219.7B) | (211.2B) | (163B) | (156.3B) | (148.7B) | (126.8B) | (114B) | (103B) | (100.6B) | (86.5B) | (75.6B) | (77.9B) | (69.2B) | (60.2B) | (32.1B) | |
55.4B | 51.4B | 54.4B | 54.5B | 52.1B | 49B | 45.5B | 31.5B | 28.5B | 28.8B | 26.5B | 25.4B | 23.8B | 22.5B | 20.6B | 20.2B | 20.4B | 18.3B | 16.1B | 11.7B | |
OPERATING INCOME | ||||||||||||||||||||
(45B) | (42.9B) | (40.7B) | (46.5B) | (38.8B) | (35.1B) | (33.5B) | (27.5B) | (19B) | (18.4B) | (17.1B) | (16.6B) | (15.7B) | (15.3B) | (14.2B) | (14.1B) | (13.9B) | (12.2B) | (11.3B) | (9.3B) | |
(0.0) | (41.2B) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (14.2B) | (14.1B) | (13.9B) | (12.2B) | (11.3B) | (9.3B) | |
10.4B | 8.5B | 13.7B | 8B | 13.3B | 13.9B | 12B | 4B | 9.5B | 10.4B | 9.5B | 8.8B | 8B | 7.2B | 6.3B | 6.1B | 6.4B | 6B | 4.8B | 2.4B | |
PRE-TAX INCOME | ||||||||||||||||||||
(3.1B) | (3B) | (2.7B) | (2.3B) | (2.5B) | (2.9B) | (3B) | (2.6B) | (1.1B) | (1.1B) | (859M) | (615M) | (517M) | (561M) | (588M) | (539M) | (530M) | (530M) | (0.0) | (0.0) | |
-3.1B | -3B | -2.7B | -2.3B | -2.5B | -2.9B | -3B | -2.6B | -1.1B | -1.1B | -838M | -600M | -509M | -557M | -584M | -536M | -525M | -509M | 0.0 | 0.0 | |
(45B) | (1.7B) | (40.7B) | (46.5B) | (38.8B) | (35.1B) | (33.5B) | (27.5B) | (19B) | (18.4B) | (17.1B) | (16.6B) | (15.7B) | (15.3B) | (0.0) | -10M | (0.0) | -200K | (0.0) | (0.0) | |
-8.2B | -2.4B | -2.6B | -2.1B | -2.8B | -4.1B | -3B | -2.6B | -1.3B | -1.7B | -859M | -1.1B | -509M | -905M | -584M | -536M | -525M | -509M | -434.6M | -215.8M | |
2.1B | 6.1B | 11.2B | 5.8B | 10.5B | 9.8B | 9B | 1.4B | 8.3B | 8.6B | 8.6B | 7.7B | 7.5B | 6.3B | 5.7B | 5.6B | 5.9B | 5.5B | 4.4B | 2.2B | |
NET INCOME | ||||||||||||||||||||
(408M) | (1.6B) | (2.8B) | (1.5B) | (2.5B) | (2.6B) | (2.4B) | (2B) | (1.6B) | (3.3B) | (3.4B) | (3B) | (2.9B) | (2.4B) | (2.3B) | (2.2B) | (2.2B) | (2.2B) | (1.7B) | (856.9M) | |
1.8B | 4.6B | 8.3B | 4.3B | 8B | 7.2B | 6.6B | -594M | 6.6B | 5.3B | 5.2B | 4.6B | 4.6B | 3.9B | 3.5B | 3.4B | 3.7B | 3.2B | 2.6B | 1.4B |
SEC Filings
CVS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 18, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 06, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 06, 2026 | May 06, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 03, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 18, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 10, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | December 09, 2025 | December 09, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 20, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | October 29, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CVS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.